Our firm’s attorneys have worked with whistleblowers to recover billions of dollars in State and Federal money lost to fraud. Read about some of their settlements and cases below.

Advanced Care Scripts Inc., $1.4 million

United States of America ex rel. Paul Nee v. Biogen, Inc., et. al. District of Massachusetts. GBB attorneys settled this qui tam suit against Advanced Care Scripts and Biogen, one of the worlds’ largest pharmaceutical companies. The complaint, filed by a whistleblower under the False Claims Act, alleged that Defendants used charitable organizations in a kickback scheme to […]

Biogen Inc., $22 million

United States of America ex rel. Paul Nee v. Biogen, Inc., et. al. District of Massachusetts. GBB attorneys settled this qui tam suit against Advanced Care Scripts and Biogen, one of the worlds’ largest pharmaceutical companies. The complaint, filed by a whistleblower under the False Claims Act, alleged that Defendants used charitable organizations in a kickback scheme to […]

Geissler v. Sterling

District of South Carolina. GBB lawyers contributed to this class action lawsuit, filed against the Department of Correction, alleging that South Carolina prisoners recieved inadequate testing and treatment for hepatitis C (HCV). The complaint accuses DOC director Bryan Sterling of “deliberate indifference” by neglecting to implement regular testing and effective treatment protocols, because it would […]

Hudson Valley Hematology Oncology Associates, $5.3 million

U.S. ex rel. Abrahamsen v. Hudson Valley, Southern District of New York. Firm attorneys brought a qui tam suit against Hudson Valley Hematology Oncology Associates (Hudson Valley), a New York based treatment center for patients with blood disorders and cancer. The complaint alleges that Hudson Valley illegally billed Medicare and Medicaid for services that were […]

Oral Roberts University, $300,000

United States ex rel. Shoe v. Oral Roberts University, District of South Carolina. GBB attorney’s brought this False Claims Act case against Oklahoma based ORU alleging that the university had fraudulently billed the Department of Education after violating the federal ban on incentive-based compensation. The whistleblower contended that ORU hired Shoe Inc., a student recruiting […]

Boeing Company, $40 million

US Ex Rel. Roby v. Boeing Co., Southern District of Ohio. Firm attorneys represented the relator in this False Claims Act suit alleging that the Boeing Company defrauded the US Government by manufacturing and selling the Army helicopters with defective parts. The Government contends that Boeing used faulty transmission gears that resulted in the crash […]

North Greenville University, $2.5 million

United States ex rel. Shoe v. North Greenville University, District of South Carolina. Firm attorneys pursued a False Claims Act suit against North Greenville University, alleging NGU illegally submitted student aid claims to the government after providing incentive compensation to student recruiters. Title IV of the Higher Education Act makes it a crime for higher [...]

Lockheed Martin, $5 million

United States, ex rel. John David Tillson, Natural Resources Defense Council, Inc., et al. v. Lockheed Martin Corp., et al., Western District of Kentucky. Lawyers with our firm represented a whistleblower in a suit alleging that Lockheed Martin Corporation and its subsidiaries violated the Resource Conservation and Recovery Act and the False Claims Act then […]

Northwell Health, $12 million

United States of America ex rel. George Markelson, et. al. v. David B. Samadi, M.D. and Northwell Health, Inc. et al., Southern District of Florida. GBB attorneys represented one of three whistleblowers in a False Claims Act suit against NY health network Northwell Health, Inc. and it’s subsidiary Lenox Hill Hospital. Whistleblowers alleged that Northwell […]

Humana Inc., $7 million

U.S., ex rel. Graves v. Plaza Med. Centers Corp., Humana Inc., and Michael Cavanaugh, Southern District of Florida. Our attorneys contributed to a qui tam action alleging that defendant Michael Cavanaugh, a doctor at Plaza Medical Centers Corporation (PMC), over-diagnosed patients with illness or complications then fraudulently billed Medicare for services. Cavanaugh’s false Medicare claims […]

Bank of America, $95 million

U.S. ex rel. Szymoniak v. Bank of America, et al., District of South Carolina / Western District of North Carolina. Firm attorneys played a role in a False Claims Act recovery from mortgage servicer Bank of America on behalf of the government. Bank of America and several other major banks paid a total of $95 […]

Amgen, $24.9 million

U.S. ex rel. Kurnik v. Amgen, Inc., et al., District of South Carolina. Firm attorneys represented Relator Frank Kurnik, in a case where pharmaceutical giant Amgen was alleged to have paid kickbacks to long-term care pharmacies to place elderly patients in nursing homes across the nation on the company’s anemia drug, Aranesp, often without concern […]

Pfizer (Rapamune), $257.4 million

U.S. ex rel. Sandler and Paris v. Wyeth Pharmaceuticals and Pfizer, Inc., Eastern District of Pennsylvania. The firm’s attorneys served as lead counsel for two whistleblowers who alleged marketing abuses of Pfizer subsidiary Wyeth Pharmaceutical’s immunosuppressant drug Rapamune. After initially declining to participate in the case, the Justice Department ultimately intervened after being presented with […]

Pfizer, $2.3 billion

U.S. ex rel. Demott v. Pfizer, District of Massachusetts. Firm attorneys represented one of six whistleblowers who revealed information to the government that resulted in an overall $2.3 billion recovery for the federal and state governments.

GlaxoSmithKline, $1.04 billion

U.S. ex rel. Graydon v. GlaxoSmithKline, District of Massachusetts. Firm attorneys served as lead counsel for whistleblowers alleging that GlaxoSmithKline (GSK) engaged in illegal promotion of the company’s popular asthma and Chronic Obstructive Pulmonary Disease (COPD) medication, Advair. The case culminated in a $1.04 billion recovery for the federal and state governments.

Community Health Systems, $97 million

U.S. ex rel. Doghramji, et al. v. Community Health Systems Inc., et al., Middle District of Tennessee. Firm attorneys represented three relators in a case alleging healthcare fraud by Tennessee-based company Community Health Systems, Inc. (“CHS”). The scheme to defraud the Medicare system jeopardized patients safety by unnecessarily hospitalizing patients and  preventing patients suffering from […]

Abbott Labs, $1.6 billion

U.S. ex rel. McCoyd v. Abbott Laboratories, Western District of Virginia. The firm’s attorneys, in conjunction with state and federal governments, pursued claims against Abbot Laboratories, alleging that Abbot unlawfully marketed its anti-epileptic drug, Depakote, to children and nursing home patients.  Their efforts on behalf of the lead whistleblower lead to a $1.6 billion recovery […]

Celgene Corporation, $280 million

U.S. ex rel. Brown v. Celgene Corporation, Central District of California. GBB recovered $280 million in a non-intervened False Claims Act case against Celgene Corporation on the eve of trial. The Complaint alleged that Celgene unlawfully marketed its drugs Thalomid and Revlimid, including for unsafe and ineffective uses, and subverted independent judgment of medical professionals […]

HAVE YOU WITNESSED FRAUD BUT DON'T KNOW WHERE TO TURN?

Talk to us! Our attorneys can help. Call Now! 202-800-3001

WATCH: Getting Started